This study aimed to evaluate the association between best tumor burden change (BTBC) in target lesions and both prognosis and toxicity in Japanese patients with stage IV MM receiving PD‐1 monotherapy as first‐line treatment. This evidence concerns the gene PDCD1 and neoplasm.